DHDiAnna L. Hynds

DiAnna L. Hynds

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


DiAnna L. Hynds has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Diane M. Snow

    Department of Anatomy and Neurobiology, University of Kentucky Medical Center, Lexington, Kentucky

    6 shared publications
  • Somesree GhoshMitra

    Department of Biology, Texas Woman's University, P.O. Box 425799, Denton, TX 76204, USA

    4 shared publications
  • Allan J. Yates

    Department of Pathology, The Ohio State University College of Medicine, Columbus, Ohio 43210 USA

    3 shared publications
  • Nathaniel C. Mills

    3 shared publications
  • Santaneel Ghosh

    Department of Engineering and Technology, Southeast Missouri State University, Cape Girardeau, One University Plaza, MO, 63701, USA

    3 shared publications
  • Santaneel Ghosh

    Nano-Bio Engineering Laboratory, Southeast Missouri State University, Cape Girardeau, MO 63701, USA

    3 shared publications

Latest Publications

  • Open Access

    Uptake of surface-functionalized thermo-responsive polymeric nanocarriers in corticospinal tract motor neurons

    by Remya Ammassam Veettil, Sumod Sebastian, Thomas McCallister, Santaneel Ghosh, DiAnna L. Hynds


  • Regulation of Small GTPase Prenylation in the Nervous System

    by Jairus M. Reddy, Namrata G. R. Raut, Jennifer L. Seifert, DiAnna L. Hynds

    Mevalonate pathway inhibitors have been extensively studied for their roles in cholesterol depletion and for inhibiting the prenylation and activation of various proteins. Inhibition of protein prenylation has potential therapeutic uses against neurological disorders, like neural cancers, neurodegeneration, and neurotramatic lesions. Protection against neurodegeneration and promotion of neuronal regeneration is regulated in large part by Ras superfamily small guanosine triphosphatases (GTPases), particularly the Ras, Rho, and Rab subfamilies. These proteins are prenylated to target them to cellular membranes. Prenylation can be specifically inhibited through altering the function of enzymes of the mevalonate pathway necessary for isoprenoid production and attachment to target proteins to elicit a variety of effects on neural cells. However, this approach does not address how prenylation affects a specific protein. This review focuses on the regulation of small GTPase prenylation, the different techniques to inhibit prenylation, and how this inhibition has affected neural cell processes.


  • Non-prenylatable, cytosolic Rac1 alters neurite outgrowth while retaining the ability to be activated

    by Jairus M. Reddy, Filsy G. Samuel, Jordan A. McConnell, Cristina P. Reddy, Brian W. Beck, DiAnna L. Hynds


  • Open Access

    Subcellular localization of Rho GTPases: implications for axon regeneration

    by DiAnna L Hynds

    Neural Regen Res, Official publication of Publishing House of Neural Regeneration Research China Association of Rehabilitation Medicine,China


  • Inhibiting Geranylgeranylation Increases Neurite Branching and Differentially Activates Cofilin in Cell Bodies and Growth Cones

    by Filsy Samuel, Jairus Reddy, Radhika Kaimal, Vianey Segovia, Huanbiao Mo, DiAnna L. Hynds

    Inhibitors of the mevalonate pathway, including the highly prescribed statins, reduce the production of cholesterol and isoprenoids such as geranylgeranyl pyrophosphates. The Rho family of small guanine triphosphatases (GTPases) requires isoprenylation, specifically geranylgeranylation, for activation. Because Rho GTPases are primary regulators of actin filament rearrangements required for process extension, neurite arborization, and synaptic plasticity, statins may affect cognition or recovery from nervous system injury. Here, we assessed how manipulating geranylgeranylation affects neurite initiation, elongation, and branching in neuroblastoma growth cones. Treatment with the statin, lovastatin (20 μM), decreased measures of neurite initiation by 17.0 to 19.0 % when a source of cholesterol was present and increased neurite branching by 4.03- to 9.54-fold (regardless of exogenous cholesterol). Neurite elongation was increased by treatment with lovastatin only in cholesterol-free culture conditions. Treatment with lovastatin decreased growth cone actin filament content by up to 24.3 %. In all cases, co-treatment with the prenylation precursor, geranylgeraniol (10 μM), reversed the effect of lovastatin. In a prior work, statin effects on outgrowth were linked to modulating the actin depolymerizing factor, cofilin. In our assays, treatment with lovastatin or geranylgeraniol decreased cofilin phosphorylation in whole cell lysates. However, lovastatin increased cofilin phosphorylation in cell bodies and decreased it in growth cones, indicating differential regulation in specific cell regions. Together, we interpret these data to suggest that protein geranylgeranylation likely regulates growth cone actin filament content and subsequent neurite outgrowth through mechanisms that also affect actin nucleation and polymerization.


  • Moderate Level Exposure to Magnetic Nanodots Encased in Tunable Poly(ethylene glycol) Analouge Biopolymer Shell Do Not Deleteriously Affect Neurite Outgrowth

    by Somesree GhoshMitra, David R. Diercks, Nathaniel C. Mills, Di Anna L. Hynds, Santaneel Ghosh

    Recently, huge interest has been generated in investigating the possible therapeutic use of tunable magnetic nanostructures to overcome the existing challenges to treat central nervous system damage related conditions. However, several issues (e.g., biocompatibility or remote controlled actuation for multi-modal therapeutics) limit the use of conventional magnetic nanoparticles for biomedical applications. To address many of these shortcomings, we have synthesized a monodisperse nanoscale system consisting highly water dispersible magnetic nanodots encased in a remotely tunable polyethylene glycol analouge biopolymer shell. The monodisperse nature of the nanospheres, their response to external magnetic field and volumetric transition near physiological temperatures are very attractive, especially for drug delivery systems where triggered release is necessary. To further analyze the potential for combinatorial therapeutics for central nervous system damage related conditions, we have explored the efficiency of the uptake of nanospheres into pheochromocytoma cell line 12 (PC12) cells and assessed several additional measures of neurite outgrowth. We find that nanospheres were readily incorporated into the cytosolic compartment within 3 hours and did not alter the morphology of cellular processes compared to cells not exposed to nanospheres. Quantification of neurite outgrowth did not reveal any significant differences in neurite initiation or elongation between cells treated with moderate level nanomagnet exposure compared to control cultures under similar conditions. Thus, this study reports an attractive nano-scale system with great potential to deliver therapeutics to precise locations within the nervous system for axonal outgrowth and guidance.


  • Role of engineered nanocarriers for axon regeneration and guidance: Current status and future trends

    by Somesree GhoshMitra, David R. Diercks, Nathaniel C. Mills, DiAnna L. Hynds, Santaneel Ghosh


  • Open Access

    Evaluation of the Biological Effects of Externally Tunable, Hydrogel Encapsulated Quantum Dot Nanospheres in Escherichia coli

    by Somesree GhoshMitra, Tong Cai, David Diercks, Zhibing Hu, James Roberts, Jai Dahiya, Nathaniel Mills, DiAnna Hynds, Santaneel Ghosh

    Quantum Dots (QDs) have become an interesting subject of study for labeling and drug delivery in biomedical research due to their unique responses to external stimuli. In this paper, the biological effects of a novel hydrogel based QD nano-structure on E. coli bacteria are presented. The experimental evidence reveals that cadmium telluride (CdTe) QDs that are encapsulated inside biocompatible polymeric shells have reduced or negligible toxicity to this model cell system, even when exposed at higher dosages. Furthermore, a preliminary gene expression study indicates that QD-hydrogel nanospheres do not inhibit the Green Fluorescent Protein (GFP) gene expression. As the biocompatible and externally tunable polymer shells possess the capability to control the QD packing density at nanometer scales, the resulting luminescence efficiency of the nanostructures, besides reducing the cytotoxic potential, may be suitable for various biomedical applications.


  • Mevalonate depletion mediates the suppressive impact of geranylgeraniol on murine B16 melanoma cells

    by Rajasekhar Katuru, Nicolle V Fernandes, Manal Elfakhani, Dibyendu Dutta, Nathaniel Mills, DiAnna L Hynds, Clay King, Huanbiao Mo

    The diterpene geranylgeraniol (all trans-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraen-1-ol) suppresses the growth of human liver, lung, ovary, pancreas, colon, stomach and blood tumors with undefined mechanisms. We evaluated the growth-suppressive activity of geranylgeraniol in murine B16 melanoma cells. Geranylgeraniol induced dose-dependent suppression of B16 cell growth (IC50 = 55 ± 13 µmol/L) following a 48-h incubation in 96-well plates. Cell cycle arrest at the G1 phase, manifested by a geranylgeraniol-induced increase in the G1/S ratio and decreased expression of cyclin D1 and cyclin-dependent kinase 4, apoptosis detected by Guava Nexin™ assay and fluorescence microscopy following acridine orange and ethidium bromide dual staining, and cell differentiation shown by increased alkaline phosphatase activity, contributed to the growth suppression. Murine 3T3-L1 fibroblasts were 10-fold more resistant than B16 cells to geranylgeraniol-mediated growth suppression. Geranylgeraniol at near IC50 concentration (60 µmol/L) suppressed the mRNA level of 3-hydroxy-3-methylglutaryl coenzyme A (HMG‐CoA) reductase by 50%. The impact of geranylgeraniol on B16 cell growth, cell cycle arrest and apoptosis were attenuated by supplemental mevalonate, the product of HMG‐CoA reductase that is essential for cell growth. Geranylgeraniol and d- δ-tocotrienol, a down-regulator of HMG‐CoA reductase, additively suppressed the growth of B16 cells. These results support our hypothesis that mevalonate depletion mediates the tumor-specific growth-suppressive impact of geranylgeraniol. Geranylgeraniol may have potential in cancer chemoprevention and/or therapy.


  • Excellent biocompatibility of semiconductor quantum dots encased in multifunctional poly(N-isopropylacrylamide) nanoreservoirs and nuclear specific labeling of growing neurons

    by Somesree GhoshMitra, David R. Diercks, Nathaniel C. Mills, DiAnna L. Hynds, Santaneel Ghosh

    Quantum dots (QDs) have received attention for labeling biomolecules; however, toxicity of these nanostructures in the intracellular environment has prevented a biomedical breakthrough. Here we report biocompatibility of a QD based multifunctional system on neuronal cells. Moreover, the designed nanostructures bind with high affinity in the cell nucleus. Nucleus specific binding and enhanced biocompatibility, coupled with no deleterious effects on neurite outgrowth, even at high dosages (500 μg/ml sphere conc.) suggest increased therapeutic potential of this system for specific targeting followed by controlled release of drugs in treating neurodegenerative disorders.